Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Open Access
- 7 July 2020
- Vol. 9 (7), 1638
- https://doi.org/10.3390/cells9071638
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease, which is characterized by lipid accumulation in hepatocytes, which can progress to non-alcoholic steatohepatitis (NASH) with inflammation and various levels of fibrosis that further increase the risk of developing cirrhosis and hepatocellular carcinoma. The pathogenesis of NAFLD is influenced by interactions between genetic and environmental factors and involves several biological processes in multiple organs. No effective therapy is currently available for the treatment of NAFLD. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate many functions that are disturbed in NAFLD, including glucose and lipid metabolism, as well as inflammation. Thus, they represent relevant clinical targets for NAFLD. In this review, we describe the determinants and mechanisms underlying the pathogenesis of NAFLD, its progression and complications, as well as the current therapeutic strategies that are employed. We also focus on the complementary and distinct roles of PPAR isotypes in many biological processes and on the effects of first-generation PPAR agonists. Finally, we review novel and safe PPAR agonists with improved efficacy and their potential use in the treatment of NAFLD.Funding Information
- Agence Nationale de la Recherche (Hepadialogue)
- Lee Kong Chian School of Medicine (Start-Up Grant)
This publication has 426 references indexed in Scilit:
- Variant in the glucokinase regulatory protein ( GCKR ) gene is associated with fatty liver in obese children and adolescentsHepatology, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver diseaseHepatology, 2010
- Pioglitazone: More than just an insulin sensitizerHepatology, 2009
- Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial designContemporary Clinical Trials, 2009
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin ResistanceCell Metabolism, 2008
- Hepatic Steatosis in Leptin-Deficient Mice Is Promoted by the PPARγ Target Gene Fsp27Cell Metabolism, 2008
- Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in miceHepatology, 2007
- PPARs and molecular mechanisms of transrepressionBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21Cell Metabolism, 2007